DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

ImmunoGen (NASDAQ: IMGN)

company name or ticker

Earnings Reaction History: ImmunoGen, Inc., 42.9% Follow-Through Indicator, 5.8% Sensitive

JPMorgan Healthcare Conference Highlights: ImmunoGen

ImmunoGen kicks off the JPMorgan Healthcare Conference by focusing on its wholly-owned compounds and emphasizing its new linking technology.

AbbVie Inc. Invests in Precision-Bombing Cancer Therapies

With annual sales likely to reach $10 billion, Humira is rocking. The party can't last forever, though. AbbVie could be filling that gap it leaves behind with an exciting new way to fight cancer.

CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

"Star Trek" Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods

The next-generation of cancer-fighting agents could be right around the corner.

Will Seattle Genetics Have a Happy New Year?

This biopharma could be a big winner in the New Year.

ImmunoGen Amends Lilly Agreement - Analyst Blog

ImmunoGen's CEO Presents at Oppenheimer 24th Annual Healthcare Conference (Transcript)

The 3 Biggest Medical Advances of 2013

Let’s take a look back at how Halozyme, Roche, ImmunoGen, and Gilead Sciences achieved the three biggest medical advances of 2013.

11 Game-Changing Drugs Approved by the FDA in 2013

In counting down our 12 Foolish Days of Christmas, we turn our attention to the 11 most important FDA approval of 2013. See which drugs could be ready to turn on the afterburners in 2014 and which patients can expect big improvements in quality of life.
See More Articles...